This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Indian Pharmaceutical Market Outlook - Enhanced Purchasing Power, Rural Market Penetration And Expanded Access To Healthcare Attracting Big Pharma Investment

 

 

List of Figures

 

Figure 1: Pharmaceutical Market, India, ANDA Filings by Indian Companies, 2012 11

Figure 2: Pharmaceutical Market, India, Growth in Pharmaceutical Products Trade, (%), 2006–2011 12

Figure 3: Pharmaceutical Market, India, Population by Age Group (%), 2001–2026 13

Figure 4: Pharmaceutical Market, India, Crude Death Rate (per 1,000 Population), 1981–2009 15

Figure 5: Pharmaceutical Market, India, Infant Mortality Rate by Sex (per 1,000 Live Births), 1980–2009 16

Figure 6: Pharmaceutical Market, India, Life Expectancy at Birth, 1901–2025 17

Figure 7: Pharmaceutical Market, India, Healthcare Indicators in BRIC Countries, 2012 18

Figure 8: Pharmaceutical Market, India, Drivers and Barriers, 2012 19

Figure 9: Pharmaceutical Market, India, Doctors and Nurses (per 10,000 population), 2010 20

Figure 10: Pharmaceutical Market, India, SWOT Analysis 22

Figure 11: Pharmaceutical Market, India, NRHM Progress, 2011 24

Figure 12: Pharmaceutical Market, India, Intellectual Property Rights Protection Framework, 2010 25

Figure 13: Pharmaceutical Market, India, Regulatory Landscape, Intellectual Property Rights Protection, 1963–2005 26

Figure 14: Pharmaceutical Market, India, Drug Distribution System, 2012 28

Figure 15: Pharmaceutical Market, India, Healthcare Expenditure, 2009 34

Figure 16: Pharmaceutical Market, India, Healthcare Expenditure among BRIC Countries, 2012 34

Figure 17: Pharmaceutical Market, India, Health Insurance Companies Landscape, 2012 36

Figure 18: Pharmaceutical Market, India, Services Outsourced in Value Chain (%), 2011 37

Figure 19: Pharmaceutical Market, India, Biotechnology Market Revenue ($m), 2003–2011 38

Figure 20: Pharmaceutical Market, India, Biotechnology Market Segmentation (%), 2011 39

Figure 21: Pharmaceutical Market, India, Market by Sub-sector (%), 2011 43

Figure 22: Pharmaceutical Market, India, Retail Market Revenue ($bn), 2007–2011 44

Figure 23: Pharmaceutical Market, India, Hospital Market Revenue ($m), 2007–2011 45

Figure 24: Pharmaceutical Market, India, Market Share by Therapy Area, 2005 and 2010 46

Figure 25: Pharmaceutical Market, India, Anti-Infectives Market Revenue ($bn), 2005–2010 47

Figure 26: Pharmaceutical Market, India, Cardiovascular Market Revenue ($m), 2005–2010 49

Figure 27: Pharmaceutical Market, India, Gastrointestinal Market Revenue ($m), 2005–2010 51

Figure 28: Pharmaceutical Market, India, Diabetes Market Revenue ($m), 2005–2010 53

Figure 29: Pharmaceutical Market, India, Central Nervous System Market Revenue ($m), 2005–2010 55

Figure 30: Pharmaceutical Market, India, Respiratory Market Revenue ($m), 2005–2010 57

Figure 31: Pharmaceutical Market, India, Dermatology Market Revenue ($m), 2005–2010 59

Figure 32: Pharmaceutical Market, India, Oncology Market Revenue ($m), 2005–2010 61

Figure 33: Pharmaceutical Market, India, Number of M&A Deals, 2007–2012 63

Figure 34: Pharmaceutical Market, India, M&A Deals, Deals by Value (%), 2007–2012 64

Figure 35: Pharmaceutical Market, India, Number of Licensing Deals, 2007–2012 65

Figure 36: Pharmaceutical Market, India, Licensing Deals, Deals by Value (%), 2007–2012 65

Figure 37: Pharmaceutical Market, India, Number of Partnership Deals, 2007–2012 66

Figure 38: Pharmaceutical Market, India, Partnership Deals, Deals by Value (%), 2007–2012 66

Figure 39: Pharmaceutical Market, India, Novartis Arogya Parivar Marketing Mix, 2012 68

Figure 40: Pharmaceutical Market, India, Novartis Arogya Parivar, Factsheet, 2012 69

Figure 41: Pharmaceutical Market, India, Mankind Sales Strategies, 2012 71

 

6 of 7

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,380.41 +263.17 1.63%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs